Georgakopoulou EA, Achtari
MD, Evangelou K, Kittas C.
Oral non-Hodgkin’s lymphoma in a patient with rheumatoid arthritis treated with
etanercept and methotrexate.
J Clin Exp Dent. 2015;7(1):e180-2.
doi:10.4317/jced.51922
References
1. Jaffe ES. The 2008 WHO
classification of lymphomas: implications for clinical practice and
translational research. Hematology Am Soc Hematol Educ Program. 2009:523-31.
http://dx.doi.org/10.1182/asheducation-2009.1.523
PMid:20008237
2. Ma S, Zhang Y, Huang J, Han
X, Holford T, Lan Q, et al.
Identification of non-Hodgkin's lymphoma prognosis signatures using the CTGDR
method. Bioinformatics. 2010;26:15-21.
http://dx.doi.org/10.1093/bioinformatics/btp604
PMid:19850755
PMCid:PMC2796812
3. Levi F, Lucchini
F, Negri E, La Vecchia C.
Trends in mortality from non-Hodgkin's lymphomas. Leuk
Res. 2002;26:903-8.
http://dx.doi.org/10.1016/S0145-2126(02)00031-0
PMid: 12163051
4. Wu XC, Andrews P, Chen VW,
Groves FD. Incidence of extranodal non-Hodgkin
lymphomas among whites, blacks, and Asians/Pacific Islanders in the United
States: anatomic site and histology differences. Cancer Epidemiol. 2009;33:337-46.
http://dx.doi.org/10.1016/j.canep.2009.09.006
PMid:19853554
5. Kolokotronis
A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, et al.
Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial
region: a clinical study. Oral Surg
Oral Med Oral Pathol Oral Radiol
Endod. 2005;99:303-10.
http://dx.doi.org/10.1016/j.tripleo.2004.03.028
PMid:15716836
6. Zapater
E, Bagan JV, Carbonell F, Basterra J. Malignant lymphoma of the head and neck. Oral
Dis. 2010;16:119-28.
http://dx.doi.org/10.1111/j.1601-0825.2009.01586.x
PMid:20374502
7. Smedby
KE, Baecklund E, Askling J.
Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk
factors, and lymphoma characteristics. Cancer Epidemiology
Biomarkers & Prevention. 2006;15:2069-77.
http://dx.doi.org/10.1158/1055-9965.EPI-06-0300
PMid:17119030
8. Georgakopoulou
EA, Andreadis D, Arvanitidis
E, Loumou P. Biologic agents and oral diseases--an
update on clinical applications. Acta dermatovenerologica Croatica:
ADC. 2013;21:24-34.
PMid:23683483
9. Cron
RQ, Beukelman T. Guilt by association-what is the
true risk of malignancy in children treated with etanercept
for JIA? Pediatric Rheumatology Online Journal. 2010;8:23.
http://dx.doi.org/10.1186/1546-0096-8-23
PMid:20712883
PMCid:PMC2931479
10. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM.
Tumor necrosis factor antagonist therapy and lymphoma development: twenty‐six
cases reported to the Food and Drug Administration. Arthritis
& Rheumatism. 2002;46:3151-8.
http://dx.doi.org/10.1002/art.10679
PMid:12483718
11. Georgakopoulou
EA, Scully C. Orofacial adverse effects of biological
agents. Journal of investigative and clinical dentistry.
2014.
PMid:24850782
12. Parihar
S, Garg RK, Narain P.
Primary extra-nodal non-Hodgkin's lymphoma of gingiva:
A diagnostic dilemma. Journal of oral and maxillofacial pathology: JOMFP. 2013;17:320.
http://dx.doi.org/10.4103/0973-029X.119773
PMid:24250108
PMCid:PMC3830256